Literature DB >> 27294429

The Role of Intuition in Risk/Benefit Decision-Making in Human Subjects Research.

David B Resnik1.   

Abstract

One of the key principles of ethical research involving human subjects is that the risks of research to should be acceptable in relation to expected benefits. Institutional review board (IRB) members often rely on intuition to make risk/benefit decisions concerning proposed human studies. Some have objected to using intuition to make these decisions because intuition is unreliable and biased and lacks transparency. In this article, I examine the role of intuition in IRB risk/benefit decision-making and argue that there are practical and philosophical limits to our ability to reduce our reliance on intuition in this process. The fact that IRB risk/benefit decision-making involves intuition need not imply that it is hopelessly subjective or biased, however, since there are strategies that IRBs can employ to improve their decisions, such as using empirical data to estimate the probability of potential harms and benefits, developing classification systems to guide the evaluation of harms and benefits, and engaging in moral reasoning concerning the acceptability of risks.

Entities:  

Keywords:  Benefits; human subjects research; institutional review boards; intuition; reasoning; risks

Mesh:

Year:  2016        PMID: 27294429      PMCID: PMC5126729          DOI: 10.1080/08989621.2016.1198978

Source DB:  PubMed          Journal:  Account Res        ISSN: 0898-9621            Impact factor:   2.622


  42 in total

1.  What makes clinical research ethical?

Authors:  E J Emanuel; D Wendler; C Grady
Journal:  JAMA       Date:  2000 May 24-31       Impact factor: 56.272

Review 2.  The ethical analysis of risk.

Authors:  C Weijer
Journal:  J Law Med Ethics       Date:  2000       Impact factor: 1.718

Review 3.  Casuistry and principlism: the convergence of method in biomedical ethics.

Authors:  M Kuczewski
Journal:  Theor Med Bioeth       Date:  1998-12

4.  Assessing risk/benefit for trials using preclinical evidence: a proposal.

Authors:  Jonathan Kimmelman; Valerie Henderson
Journal:  J Med Ethics       Date:  2015-10-13       Impact factor: 2.903

5.  Protecting third parties in human subjects research.

Authors:  David B Resnik; Richard R Sharp
Journal:  IRB       Date:  2006 Jul-Aug

6.  Assessing research risks systematically: the net risks test.

Authors:  D Wendler; F G Miller
Journal:  J Med Ethics       Date:  2007-08       Impact factor: 2.903

7.  Balancing scientific and community interests in community-based participatory research.

Authors:  David B Resnik; Caitlin E Kennedy
Journal:  Account Res       Date:  2010-07       Impact factor: 2.622

Review 8.  How do IRB members make decisions? A review and research agenda.

Authors:  Ivor A Pritchard
Journal:  J Empir Res Hum Res Ethics       Date:  2011-06       Impact factor: 1.742

9.  How do institutional review boards apply the federal risk and benefit standards for pediatric research?

Authors:  Seema Shah; Amy Whittle; Benjamin Wilfond; Gary Gensler; David Wendler
Journal:  JAMA       Date:  2004-01-28       Impact factor: 56.272

10.  Assessment of the risk/benefit ratio of phase II cancer clinical trials by Institutional Review Board (IRB) members.

Authors:  H E M Van Luijn; A W Musschenga; R B Keus; W M Robinson; N K Aaronson
Journal:  Ann Oncol       Date:  2002-08       Impact factor: 32.976

View more
  4 in total

1.  Minimal Risk in Pediatric Research: A Philosophical Review and Reconsideration.

Authors:  John Rossi; Robert M Nelson
Journal:  Account Res       Date:  2017-08-04       Impact factor: 2.622

2.  Standards of evidence for institutional review board decision-making.

Authors:  David B Resnik
Journal:  Account Res       Date:  2020-12-08       Impact factor: 3.057

3.  Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment.

Authors:  Gail E Henderson; Holly L Peay; Eugene Kroon; Rosemary Jean Cadigan; Karen Meagher; Thidarat Jupimai; Adam Gilbertson; Jill Fisher; Nuchanart Q Ormsby; Nitiya Chomchey; Nittaya Phanuphak; Jintanat Ananworanich; Stuart Rennie
Journal:  J Med Ethics       Date:  2017-11-10       Impact factor: 2.903

4.  Efficacy, safety and cost-effectiveness of hydroxychloroquine in children with COVID-19: A call for evidence.

Authors:  Carlos E Rodríguez-Martínez; Ricardo M Fernandes; Daniel B Hawcutt; Ian P Sinha; Rafael Leite Pacheco
Journal:  Acta Paediatr       Date:  2020-06-03       Impact factor: 4.056

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.